These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18687447)

  • 1. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
    Ko MW; Tamhankar MA; Volpe NJ; Porter D; McGrath C; Galetta SL
    J Neurol Sci; 2008 Oct; 273(1-2):144-7. PubMed ID: 18687447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone-related acute leukemia in two MS patients.
    Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
    Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.
    Sumrall A; Dreiling B
    J Miss State Med Assoc; 2007 Jul; 48(7):206-7. PubMed ID: 17939254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
    Cattaneo C; Almici C; Borlenghi E; Motta M; Rossi G
    Leukemia; 2003 May; 17(5):985-6. PubMed ID: 12750718
    [No Abstract]   [Full Text] [Related]  

  • 6. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
    Novoselac AV; Reddy S; Sanmugarajah J
    Leukemia; 2004 Sep; 18(9):1561-2. PubMed ID: 15215874
    [No Abstract]   [Full Text] [Related]  

  • 8. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.
    Bosca I; Pascual AM; Casanova B; Coret F; Sanz MA
    Neurology; 2008 Aug; 71(6):457-8. PubMed ID: 18678830
    [No Abstract]   [Full Text] [Related]  

  • 9. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis.
    Ledda A; Caocci G; Spinicci G; Cocco E; Mamusa E; La Nasa G
    Leukemia; 2006 Dec; 20(12):2217-8. PubMed ID: 17051242
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
    Sadiq SA; Rammal M; Sara G
    Mult Scler; 2008 Mar; 14(2):272-3. PubMed ID: 17986509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
    Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
    Hasan SK; Buttari F; Ottone T; Voso MT; Hohaus S; Marasco E; Mantovani V; Garagnani P; Sanz MA; Cicconi L; Bernardi G; Centonze D; Lo-Coco F
    Neurology; 2011 Mar; 76(12):1059-65. PubMed ID: 21346221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
    Weinstock-Guttman B; Ramanathan M; Lincoff N; Napoli SQ; Sharma J; Feichter J; Bakshi R
    Arch Neurol; 2006 Jul; 63(7):957-63. PubMed ID: 16831964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Ellis R; Boggild M
    Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.
    Zecca C; Petrini L; Limoni C; Staedler C; Gobbi C
    Eur Neurol; 2011; 65(1):40-5. PubMed ID: 21196739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis.
    Vicari AM; Ciceri F; Folli F; Lanzi R; Colombo B; Comi G; Camba L
    Leukemia; 1998 Mar; 12(3):441-2. PubMed ID: 9529141
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
    Colovic N; Suvajdzic N; Kraguljac Kurtovic N; Djordjevic V; Dencic Fekete M; Drulovic J; Vidovic A; Tomin D
    Biomed Pharmacother; 2012 Apr; 66(3):173-4. PubMed ID: 22440894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.